



Latest News

MaxCyte® Launches EXPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies

Gaithersburg, Maryland – April 8, 2019: MaxCyte, the global clinical-stage cell-based medicines and life sciences company, announced today the launch of the new EXPERT™ technology platform. This family of instruments – the ATx, STx and GTx – represents the next generation of the industry's leading, clinically validated Flow Electroporation® technology for complex cellular engineering. With these additions to the product portfolio, MaxCyte continues its uncompromising focus on high performance cellular editing, while delivering feature enhancements that will enable customers to use a single unifying technology, from concept to commercialization.

"The EXPERT instrument family is the result of extensive customer research into feature design, functionality and performance that are considered critical to enabling the next generation of cellular therapies," said Brad Calvin, Executive Vice President of Global Commercial Operations for MaxCyte. "Creating cellular editing platforms standardized on a single, scalable, high performance technology can assist the industry in accelerating timelines, reducing costs and achieving milestones critical to the translation of this promising new generation of cellular therapies."

The EXPERT ATx, STx and GTx build on the solid technology foundation that has been the core of MaxCyte's historical instrument platforms, which are broadly used by leading companies across the biopharmaceutical industry who are developing increasingly sophisticated biological and cellular-based therapeutics.

"We are proud to announce the launch of our next-generation EXPERT brand of instruments," said Doug Doerfler, MaxCyte's President and CEO. "We are committed to continually investing in our platform and delivering the essential tools, product features and technology performance that are critical to the advancement of promising new cellular therapeutics, which provide hope to many patients with previously incurable or life-threatening diseases."

The new instrument family can be viewed on-line at www.myexpertplatform.com.

About MaxCyte

MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies. The Company now has more than 70 partnered program licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

For further information, please contact:

MaxCyte Inc.

Doug Doerfler, CEO +1 301 944 1660
Brad Calvin, EVP, Global Commercial Operations

US Media Relations

Jamie Lacey-Moreira +1 410-299-3310
jamielacey@presscommpr.com

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

[Sign Up](#)

Applications

Overview
Cell/Gene Therapy
Protein Production
Cell-based Assays
Gene Editing
Cell Line Development
Viral Vectors/Vaccines

Products and Services

Technology

Overview
Flow Electroporation
Scalability
Primary & Stem Cells
Insect Cells
Cell Cryopreservation

CARMA

Overview

Investors

News and Events

Latest News
Archives
Events
Media Contact
Newsletter
Careers

Resource Center

Videos & Webinars
Posters
Application Notes & Technical Papers
Product Literature
Scientific Publications
Request Demo/Quote



[Contact Us](#)

MaxCyte, Inc.
22 Firstfield Road, Suite 110
Gaithersburg, MD 20878

Overview
MaxCylte STX
MaxCylte VLX
MaxCylte GT
Processing Assemblies
Services
Quality Systems

About Us

Overview
Senior Management
BOD
Advisors
Company History
Business Development

Overview
Current Openings

Contact

General Inquiries
Distributors

Tel: +1-301-944-1700
Fax: +1-301-944-1703



By visiting the MaxCylte.com website, you accept that we use cookies. You are anonymous as a user of the MaxCylte.com website. We do not register any information that can identify you personally. Read more about our use of cookies. [Find out more.](#)